Worst performer was TAP:Taptica dropping 13%, making me really glad I didn't invest any more thinking it had reached a bottom. The suspension of the share buy back scheme is a real worry, although in theory the reasons are good as they claim to have a potential acquisition. However why announce the buy-back in the first place? I'm glad it's just my cursed trading account and really annoyed I didn't take £100 profit when I had the chance.
OPTI:Optibiotix dropped 4p which is 6% and £3,200. There was no news this week, but that usually sees an increase. Some new trolls have appeared on the bulletin board so it's possible traders are targeting it to try and get the price down. Presumably they took their profits at 90p and want back in!
CEY:Centamin dropped 5% this week which is a surprise given that the price of gold is doing much better.
IKA:Ilika gave quite an upbeat statement today which fired a glimmer of hope they may be able to commercialise something after all. The share price is up 5% on the week, but still 62% down from when I bought them.
LLOY:Lloyds Bank are creeping back towards profit, climbing 5% this week and are only 5% down overall. I'll be getting another £1,000 from my SIPP in a few weeks so may put it here.
N4P:N4 Pharma wins Share of the Week with a 7% climb. No particular reason I can see, and a long long way before I recover my 52% loss.
All last week's gains have gone. Note I've removed the trend line as it doesn't really give a true reflection when the increase in cost isn't taken into account. That's now covered by the chart below.
So frustrating that there was such a big spike 5 months ago and it lasted such a short time. Now only just in the black but the trend line is still pointing up, and that's based on the difference between cost and value so doesn't artificially increase as the costs go up from buying more.
Here's the performance of the ISA and share accounts
| Weekly Change | |||
| Cash | £42.91 | +£0 | |
| Portfolio cost | £56,971.94 | +£0 | |
| Portfolio sell value (bid price - commission) | £58,418.21 | (2.5%) | -£2,003.29 |
| Potential profits | £10,537.49 | -£2,013.51 | |
| Yr 4 Dividends | £60.50 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £153.93 | (3.2%) | -£6.69 |
| Total Dividends | £1,298.83 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £496.92 | (10.5%) | -£2.78 |
| (Sold stocks profit + Dividends - Fees / Months) |
All losses down to reduced profit, and most of that was OPTI:Optibiotix with a small positive contribution from MTFB:Motif Bio which climbed 1%.
Still in the black but only just.
The trend line is still improving, but when the earlier lows get nudged off the left hand side of the chart, we're in for a severe reversal if the current buffer can't get back to £20K.
Here's the SIPP after week 164
| Weekly Change | |||
| Cash | £122.84 | +£0 | |
| Portfolio cost | £37,825.18 | +£0 | |
| Portfolio sell value (bid price - commission) | £41,322.19 | (9.2%) | -£1,166.94 |
| Potential profits | £7,388.28 | -£1,342.13 | |
| Yr 4 Dividends | £0 | +£0 | |
| Yr 4 Interest | £0.04 | +£0 | |
| Yr 4 Profit from sales | £0 | +£0 | |
| Yr 4 Average monthly cash profit | -£16.88 | (-0.5%) | +£2.41 |
| Total Dividends | £1,342.25 | +£0 | |
| Total Interest | £0.07 | +£0.03 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £305.82 | (9.7%) | -£1.87 |
| (Sold stocks profit + Dividends - Fees / Months) |
Similar story to the other account, but this time the rest of the portfolio fought back and managed to improve the losses by about £180. I really need to clock up some realised profit so the average can get back above 10%. For that I need some good news from SBTX:SkinBioTherapeutics as that's the best candidate for a sale. The current £37 paper profit isn't going to help my stats much though.
Looking much better than the other accounts
Still have the big spike in the middle which could disrupt the trend line later.
Here's the trading account after week 130
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,374.66 | (-40.8%) | -£43.75 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £32.40 | (16.7%) | -£1.29 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.53 | (-0.8%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
IQE:IQE helped limit the losses from other dips, as this account continues to disappoint horribly.
Still no prospect of moving the orange line down to £0.
Desperate.
That's it for this week - and finished just in time for the footie!
No comments:
Post a Comment